Literature DB >> 8935811

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

J L Martinot1, M L Paillère-Martinot, M F Poirier, M H Dao-Castellana, C Loc'h, B Mazière.   

Abstract

The relationship between the daily oral dose of the benzamide amisulpride and the striatal D2-dopamine receptors occupancy was investigated in 11 schizophrenic patients using positron emission tomography with 76Br-bromolisuride. The patients were studied before and during chronic treatment with amisulpride over a wide range of doses. The test-retest variability of the method was estimated to be 5.8% in a group of four patients receiving placebo. A curvilinear relationship was demonstrated between the amisulpride doses and the D2-receptor occupancy. A range of 70-80% occupancy of the striatal D2 receptors, suggested as an optimal interval for therapeutic action on positive psychotic symptoms, was obtained with doses of amisulpride ranging between 630 and 910 mg per day, while an occupancy of 85%, suggested to be associated with pronounced extrapyramidal side-effects, was reached with 1,100 mg per day.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935811     DOI: 10.1007/bf02245616

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

2.  In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans.

Authors:  H Cambon; J C Baron; J P Boulenger; C Loc'h; E Zarifian; B Maziere
Journal:  Br J Psychiatry       Date:  1987-12       Impact factor: 9.319

3.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

4.  [76Br]bromolisuride: a new tool for quantitative in vivo imaging of D-2 dopamine receptors.

Authors:  B Maziere; C Loc'h; O Stulzaft; P Hantraye; M Ottaviani; D Comar; M Maziere
Journal:  Eur J Pharmacol       Date:  1986-08-15       Impact factor: 4.432

5.  Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia.

Authors:  A Wolkin; F Barouche; A P Wolf; J Rotrosen; J S Fowler; C Y Shiue; T B Cooper; J D Brodie
Journal:  Am J Psychiatry       Date:  1989-07       Impact factor: 18.112

6.  3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.

Authors:  J Kornhuber; P Riederer; G P Reynolds; H Beckmann; K Jellinger; E Gabriel
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

7.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

8.  Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

Authors:  A L Nordström; L Farde; F A Wiesel; K Forslund; S Pauli; C Halldin; G Uppfeldt
Journal:  Biol Psychiatry       Date:  1993-02-15       Impact factor: 13.382

9.  The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride.

Authors:  J L Martinot; M L Paillère-Martinot; C Loc'h; P Hardy; M F Poirier; B Mazoyer; B Beaufils; B Mazière; J F Allilaire; A Syrota
Journal:  Br J Psychiatry       Date:  1991-03       Impact factor: 9.319

10.  Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.

Authors:  A Delcker; M L Schoon; B Oczkowski; H J Gaertner
Journal:  Pharmacopsychiatry       Date:  1990-05       Impact factor: 5.788

View more
  18 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen.

Authors:  Manabu Tashiro; Hideki Mochizuki; Yumiko Sakurada; Kenji Ishii; Keiichi Oda; Yuichi Kimura; Toru Sasaki; Kiichi Ishiwata; Kazuhiko Yanai
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 3.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

4.  Effects of amisulpride on human resting cerebral perfusion.

Authors:  Roberto Viviani; Heiko Graf; Maike Wiegers; Birgit Abler
Journal:  Psychopharmacology (Berl)       Date:  2013-04-13       Impact factor: 4.530

5.  Differential modulation of reinforcement learning by D2 dopamine and NMDA glutamate receptor antagonism.

Authors:  Gerhard Jocham; Tilmann A Klein; Markus Ullsperger
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

Review 6.  Amisulpride: a review of its use in the management of schizophrenia.

Authors:  M P Curran; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Amisulpride for schizophrenia.

Authors:  N E Mota; M S Lima; B G Soares
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 8.  Practical issues with amisulpride in the management of patients with schizophrenia.

Authors:  Luca Pani; José M Villagrán; Vassilis P Kontaxakis; Köksal Alptekin
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

9.  Hyperprolactinaemia with amisulpride.

Authors:  Rajnish Raj; Balwant Singh Sidhu
Journal:  Indian J Psychiatry       Date:  2008-01       Impact factor: 1.759

10.  Update on the management of symptoms in schizophrenia: focus on amisulpride.

Authors:  Ann M Mortimer
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.